SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).
暂无分享,去创建一个
D. Davar | G. Curigliano | S. Ansell | V. Ribrag | R. Sanborn | A. Forero-Torres | E. Garralda | F. Foss | J. Zain | A. Minchom | A. Mehta